Abstract
Histone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are validated drug targets for some types of cancer and are promising therapeutic targets for a range of other diseases, including malaria. Annually, there are ~500 million clinical cases of malaria and ~0.8-1.2 million deaths. There is no licensed vaccine for preventing malaria, and parasites that cause malaria are becoming resistant to current drugs, necessitating the search for new therapies. HDAC inhibitors are emerging as a promising new class of antimalarial drugs with potent and selective action against Plasmodium parasites in vitro. Recent studies on the effects of HDAC inhibitors on the growth and development of P. falciparum have provided important new information on transcriptional regulation in malaria parasites and have validated the potential of this class of inhibitors for malaria therapy. To realise effective HDAC inhibitors for clinical trials, next generation inhibitors must not inhibit other human HDACs or proteins required for normal human physiology, be highly selective in killing parasites in vivo without killing normal host cells, and have improved bioavailability and pharmacokinetic profiles. This review summarizes current knowledge about malaria parasite HDACs and HDAC inhibitors with antimalarial properties, and provides insights for their development into new drugs for treatment of malaria.
Keywords: Histone deacetylase, HDAC inhibitor, malaria, Plasmodium falciparum, antimalarial drugs, post-translational modifications, epigenetic changes, vaccine, bioavailability, pharmacokinetic profiles
Current Pharmaceutical Design
Title:Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs
Volume: 18 Issue: 24
Author(s): Katherine T. Andrews, Thanh N. Tran and David P. Fairlie
Affiliation:
Keywords: Histone deacetylase, HDAC inhibitor, malaria, Plasmodium falciparum, antimalarial drugs, post-translational modifications, epigenetic changes, vaccine, bioavailability, pharmacokinetic profiles
Abstract: Histone deacetylases (HDACs) are important enzymes that effect post-translational modifications of proteins by altering the acetylation state of lysine residues. HDACs control epigenetic changes that trigger cell transformation and proliferation of transformed cells associated with many diseases. These enzymes are validated drug targets for some types of cancer and are promising therapeutic targets for a range of other diseases, including malaria. Annually, there are ~500 million clinical cases of malaria and ~0.8-1.2 million deaths. There is no licensed vaccine for preventing malaria, and parasites that cause malaria are becoming resistant to current drugs, necessitating the search for new therapies. HDAC inhibitors are emerging as a promising new class of antimalarial drugs with potent and selective action against Plasmodium parasites in vitro. Recent studies on the effects of HDAC inhibitors on the growth and development of P. falciparum have provided important new information on transcriptional regulation in malaria parasites and have validated the potential of this class of inhibitors for malaria therapy. To realise effective HDAC inhibitors for clinical trials, next generation inhibitors must not inhibit other human HDACs or proteins required for normal human physiology, be highly selective in killing parasites in vivo without killing normal host cells, and have improved bioavailability and pharmacokinetic profiles. This review summarizes current knowledge about malaria parasite HDACs and HDAC inhibitors with antimalarial properties, and provides insights for their development into new drugs for treatment of malaria.
Export Options
About this article
Cite this article as:
T. Andrews Katherine, N. Tran Thanh and P. Fairlie David, Towards Histone Deacetylase Inhibitors as New Antimalarial Drugs, Current Pharmaceutical Design 2012; 18 (24) . https://dx.doi.org/10.2174/138161212801327257
DOI https://dx.doi.org/10.2174/138161212801327257 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
May Exercise Prevent Addiction?
Current Neuropharmacology The Use of Biomarkers for Assessing HAART-Associated Renal Toxicity in HIV-Infected Patients
Current HIV Research The Role of An Experimental Model of Atherosclerosis: apoE-knockout Mice in Developing New Drugs against Atherogenesis
Current Pharmaceutical Biotechnology New Insights in Mast Cell Modulation by Palmitoylethanolamide
CNS & Neurological Disorders - Drug Targets Phytochemistry and Pharmacological Update on Tetraterpenoids
The Natural Products Journal Editorial (Thematic Issue: Linkage of Neurodegenerative Disorders with Other Health Issues – Volume I)
CNS & Neurological Disorders - Drug Targets Thyroid Hormone Ligands and Metabolic Diseases
Current Pharmaceutical Design Vitamin D and Cystic Fibrosis Lung Disease
Mini-Reviews in Medicinal Chemistry Editorial (Thematic Issue: Health Impact and Management of a Disrupted Circadian Rhythm and Sleep in Critical Illnesses)
Current Pharmaceutical Design Developing Novel Therapeutic Approaches to Frailty
Current Pharmaceutical Design Two Cases of Glucose-6-phosphate Dehydrogenase Deficiency Presenting as Symptomatic Methemoglobinemia with Persistently Low Saturations After Fava Bean Ingestion in United Arab Emirates
Applied Clinical Research, Clinical Trials and Regulatory Affairs EDITORIAL (Hot Topic: Beyond Reproductive Effects of Sex Steroids)
Mini-Reviews in Medicinal Chemistry Regulation of Gastric Nesfatin-1/NUCB2
Current Pharmaceutical Design Liverworts-Potential Source of Medicinal Compounds
Current Pharmaceutical Design Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV
Current Topics in Medicinal Chemistry Mechanical Circulatory Support of the Critically Ill Child Awaiting Heart Transplantation
Current Cardiology Reviews Gender-Specific Aspects in Primary and Secondary Prevention of Cardiovascular Disease
Current Pharmaceutical Design Pharmacogenomics: Integration into Drug Discovery and Development
Current Topics in Medicinal Chemistry Targeting Telomerase by Antisense-Based Approaches: Perspectives for New Anti-Cancer Therapies
Current Pharmaceutical Design Noradrenaline-mediated Inhibition of Inflammatory Cytokines is Altered in Macrophages from Obese Zucker Rats: Effect of Habitual Exercise
Endocrine, Metabolic & Immune Disorders - Drug Targets